List of Tables
    Table 1. Selective Cox-2 Inhibitors Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028)
    Table 2. Selective Cox-2 Inhibitors Market Trends
    Table 3. Selective Cox-2 Inhibitors Market Drivers
    Table 4. Selective Cox-2 Inhibitors Market Challenges
    Table 5. Selective Cox-2 Inhibitors Market Restraints
    Table 6. Global Selective Cox-2 Inhibitors Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Selective Cox-2 Inhibitors Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Selective Cox-2 Inhibitors Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Selective Cox-2 Inhibitors Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Selective Cox-2 Inhibitors Companies in Global Market, Ranking by Revenue (2021)
    Table 11. Global Selective Cox-2 Inhibitors Revenue by Player, (US$ Million), 2017-2022
    Table 12. Global Selective Cox-2 Inhibitors Revenue Share by Player, 2017-2022
    Table 13. Global Selective Cox-2 Inhibitors Companies Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Selective Cox-2 Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Selective Cox-2 Inhibitors as of 2021)
    Table 15. Top Players of Selective Cox-2 Inhibitors in Global Market, Headquarters and Area Served
    Table 16. Companies Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million) Type
    Table 17. Date of International Companies Enter into Selective Cox-2 Inhibitors Market
    Table 18. Companies Mergers & Acquisitions, Expansion Plans
    Table 19. Top Selective Cox-2 Inhibitors Players in United States Market, Ranking by Revenue (2021)
    Table 20. United States Selective Cox-2 Inhibitors Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 21. United States Selective Cox-2 Inhibitors Revenue Share by Players, 2020, 2021 & 2022
    Table 22. Global Selective Cox-2 Inhibitors Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 23. Global Selective Cox-2 Inhibitors Market Size by Region (2017-2022) & (US$ Million)
    Table 24. Global Selective Cox-2 Inhibitors Market Size Forecast by Region (2023-2028) & (US$ Million)
    Table 25. North America Selective Cox-2 Inhibitors Sales in Value by Country (2017-2028) & (US$ Million)
    Table 26. Asia Pacific Selective Cox-2 Inhibitors Sales in Value by Region (2017-2028) & (US$ Million)
    Table 27. Europe Selective Cox-2 Inhibitors Sales in Value by Country (2017-2028) & (US$ Million)
    Table 28. Latin Americaa Selective Cox-2 Inhibitors Sales in Value by Country (2017-2028) & (US$ Million)
    Table 29. Middle East and Africa Selective Cox-2 Inhibitors Sales in Value by Country (2017-2028) & (US$ Million)
    Table 30. Boehringer-Ingelheim Company Details
    Table 31. Boehringer-Ingelheim Business Overview
    Table 32. Boehringer-Ingelheim Selective Cox-2 Inhibitors Product
    Table 33. Boehringer-Ingelheim Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 34. Boehringer-Ingelheim Recent Development
    Table 35. TerSera Therapeutics Company Details
    Table 36. TerSera Therapeutics Business Overview
    Table 37. TerSera Therapeutics Selective Cox-2 Inhibitors Product
    Table 38. TerSera Therapeutics Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 39. TerSera Therapeutics Recent Development
    Table 40. Iroko Pharmaceuticals Company Details
    Table 41. Iroko Pharmaceuticals Business Overview
    Table 42. Iroko Pharmaceuticals Selective Cox-2 Inhibitors Product
    Table 43. Iroko Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 44. Iroko Pharmaceuticals Recent Development
    Table 45. Apotex Company Details
    Table 46. Apotex Business Overview
    Table 47. Apotex Selective Cox-2 Inhibitors Product
    Table 48. Apotex Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 49. Apotex Recent Development
    Table 50. Yung Shin Pharmaceutical Company Details
    Table 51. Yung Shin Pharmaceutical Business Overview
    Table 52. Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Product
    Table 53. Yung Shin Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 54. Yung Shin Pharmaceutical Recent Development
    Table 55. Breckenridge Pharmaceutical Company Details
    Table 56. Breckenridge Pharmaceutical Business Overview
    Table 57. Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Product
    Table 58. Breckenridge Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 59. Breckenridge Pharmaceutical Recent Development
    Table 60. Meda Pharmaceuticals Company Details
    Table 61. Meda Pharmaceuticals Business Overview
    Table 62. Meda Pharmaceuticals Selective Cox-2 Inhibitors Product
    Table 63. Meda Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 64. Meda Pharmaceuticals Recent Development
    Table 65. Cipla Company Details
    Table 66. Cipla Business Overview
    Table 67. Cipla Selective Cox-2 Inhibitors Product
    Table 68. Cipla Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 69. Cipla Recent Development
    Table 70. Glenmark Pharmaceuticals Company Details
    Table 71. Glenmark Pharmaceuticals Business Overview
    Table 72. Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Product
    Table 73. Glenmark Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 74. Glenmark Pharmaceuticals Recent Development
    Table 75. Teva Company Details
    Table 76. Teva Business Overview
    Table 77. Teva Selective Cox-2 Inhibitors Product
    Table 78. Teva Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 79. Teva Recent Development
    Table 80. PuraCap Pharmaceutical Company Details
    Table 81. PuraCap Pharmaceutical Business Overview
    Table 82. PuraCap Pharmaceutical Selective Cox-2 Inhibitors Product
    Table 83. PuraCap Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 84. PuraCap Pharmaceutical Recent Development
    Table 85. Almirall Limited Company Details
    Table 86. Almirall Limited Business Overview
    Table 87. Almirall Limited Selective Cox-2 Inhibitors Product
    Table 88. Almirall Limited Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 89. Almirall Limited Recent Development
    Table 90. Lupin Pharmaceuticals Company Details
    Table 91. Lupin Pharmaceuticals Business Overview
    Table 92. Lupin Pharmaceuticals Selective Cox-2 Inhibitors Product
    Table 93. Lupin Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 94. Lupin Pharmaceuticals Recent Development
    Table 95. Aurobindo Pharma Company Details
    Table 96. Aurobindo Pharma Business Overview
    Table 97. Aurobindo Pharma Selective Cox-2 Inhibitors Product
    Table 98. Aurobindo Pharma Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 99. Aurobindo Pharma Recent Development
    Table 100. Pfizer Company Details
    Table 101. Pfizer Business Overview
    Table 102. Pfizer Selective Cox-2 Inhibitors Product
    Table 103. Pfizer Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 104. Pfizer Recent Development
    Table 105. Mylan Company Details
    Table 106. Mylan Business Overview
    Table 107. Mylan Selective Cox-2 Inhibitors Product
    Table 108. Mylan Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 109. Mylan Recent Development
    Table 110. Takeda Company Details
    Table 111. Takeda Business Overview
    Table 112. Takeda Selective Cox-2 Inhibitors Product
    Table 113. Takeda Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 114. Takeda Recent Development
    Table 115. Bayer Company Details
    Table 116. Bayer Business Overview
    Table 117. Bayer Selective Cox-2 Inhibitors Product
    Table 118. Bayer Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 119. Bayer Recent Development
    Table 120. Novacap Company Details
    Table 121. Novacap Business Overview
    Table 122. Novacap Selective Cox-2 Inhibitors Product
    Table 123. Novacap Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 124. Novacap Recent Development
    Table 125. Abbott Company Details
    Table 126. Abbott Business Overview
    Table 127. Abbott Selective Cox-2 Inhibitors Product
    Table 128. Abbott Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 129. Abbott Recent Development
    Table 130. Geri-Care Company Details
    Table 131. Geri-Care Business Overview
    Table 132. Geri-Care Selective Cox-2 Inhibitors Product
    Table 133. Geri-Care Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 134. Geri-Care Recent Development
    Table 135. Perrigo Company Details
    Table 136. Perrigo Business Overview
    Table 137. Perrigo Selective Cox-2 Inhibitors Product
    Table 138. Perrigo Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 139. Perrigo Recent Development
    Table 140. Kopran Company Details
    Table 141. Kopran Business Overview
    Table 142. Kopran Selective Cox-2 Inhibitors Product
    Table 143. Kopran Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 144. Kopran Recent Development
    Table 145. Merck Company Details
    Table 146. Merck Business Overview
    Table 147. Merck Selective Cox-2 Inhibitors Product
    Table 148. Merck Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 149. Merck Recent Development
    Table 150. Hengrui pharmaceutical Company Details
    Table 151. Hengrui pharmaceutical Business Overview
    Table 152. Hengrui pharmaceutical Selective Cox-2 Inhibitors Product
    Table 153. Hengrui pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 154. Hengrui pharmaceutical Recent Development
    Table 155. Kelun Group Company Details
    Table 156. Kelun Group Business Overview
    Table 157. Kelun Group Selective Cox-2 Inhibitors Product
    Table 158. Kelun Group Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 159. Kelun Group Recent Development
    Table 160. Qilu Pharmaceutical Company Details
    Table 161. Qilu Pharmaceutical Business Overview
    Table 162. Qilu Pharmaceutical Selective Cox-2 Inhibitors Product
    Table 163. Qilu Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 164. Qilu Pharmaceutical Recent Development
    Table 165. Taro Pharmaceuticals  Company Details
    Table 166. Taro Pharmaceuticals  Business Overview
    Table 167. Taro Pharmaceuticals  Selective Cox-2 Inhibitors Product
    Table 168. Taro Pharmaceuticals  Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 169. Taro Pharmaceuticals  Recent Development
    Table 170. Research Programs/Design for This Report
    Table 171. Key Data Information from Secondary Sources
    Table 172. Key Data Information from Primary Sources
List of Figures
    Figure 1. Selective Cox-2 Inhibitors Product Picture
    Figure 2. Global Selective Cox-2 Inhibitors Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Selective Cox-2 Inhibitors Market Size 2017-2028 (US$ Million)
    Figure 4. United States Selective Cox-2 Inhibitors Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 5. United States Selective Cox-2 Inhibitors Market Size 2017-2028 (US$ Million)
    Figure 6. United States Selective Cox-2 Inhibitors Market Share in Global 2017-2028
    Figure 7. Selective Cox-2 Inhibitors Report Years Considered
    Figure 8. Product Picture of Meloxicam
    Figure 9. Product Picture of Celecoxib
    Figure 10. Product Picture of Etoricoxib
    Figure 11. Product Picture of Imrecoxib
    Figure 12. Product Picture of Etodolac
    Figure 13. Product Picture of Parecoxib
    Figure 14. Product Picture of Other
    Figure 15. Global Selective Cox-2 Inhibitors Market Share by Type in 2022 & 2028
    Figure 16. Global Selective Cox-2 Inhibitors Market Size by Type (2017-2028) & (US$ Million)
    Figure 17. Global Selective Cox-2 Inhibitors Market Share by Type (2017-2028)
    Figure 18. United States Selective Cox-2 Inhibitors Market Share by Type in 2022 & 2028
    Figure 19. United States Selective Cox-2 Inhibitors Market Size by Type (2017-2028) & (US$ Million)
    Figure 20. United States Selective Cox-2 Inhibitors Market Share by Type (2017-2028)
    Figure 21. Product Picture of Rheumatoid Arthritis
    Figure 22. Product Picture of Osteoarthritis
    Figure 23. Product Picture of Spondylosis Chronica Ankylopoietica
    Figure 24. Product Picture of Other
    Figure 25. Global Selective Cox-2 Inhibitors Market Share by Application in 2022 & 2028
    Figure 26. Global Selective Cox-2 Inhibitors Market Size by Application (2017-2028) & (US$ Million)
    Figure 27. Global Selective Cox-2 Inhibitors Market Share by Application (2017-2028)
    Figure 28. United States Selective Cox-2 Inhibitors Market Share by Application in 2022 & 2028
    Figure 29. United States Selective Cox-2 Inhibitors Market Size by Application (2017-2028) & (US$ Million)
    Figure 30. United States Selective Cox-2 Inhibitors Market Share by Application (2017-2028)
    Figure 31. North America Selective Cox-2 Inhibitors Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 32. U.S. Selective Cox-2 Inhibitors Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 33. Canada Selective Cox-2 Inhibitors Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 34. Europe Selective Cox-2 Inhibitors Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 35. Germany Selective Cox-2 Inhibitors Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 36. France Selective Cox-2 Inhibitors Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 37. U.K. Selective Cox-2 Inhibitors Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 38. Italy Selective Cox-2 Inhibitors Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 39. Russia Selective Cox-2 Inhibitors Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 40. Asia-Pacific Selective Cox-2 Inhibitors Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 41. China Selective Cox-2 Inhibitors Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 42. Japan Selective Cox-2 Inhibitors Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 43. South Korea Selective Cox-2 Inhibitors Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 44. India Selective Cox-2 Inhibitors Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 45. Australia Selective Cox-2 Inhibitors Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 46. Taiwan Selective Cox-2 Inhibitors Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 47. Indonesia Selective Cox-2 Inhibitors Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 48. Thailand Selective Cox-2 Inhibitors Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 49. Malaysia Selective Cox-2 Inhibitors Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 50. Philippines Selective Cox-2 Inhibitors Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 51. Latin America Selective Cox-2 Inhibitors Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 52. Mexico Selective Cox-2 Inhibitors Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 53. Brazil Selective Cox-2 Inhibitors Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 54. Argentina Selective Cox-2 Inhibitors Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 55. Middle East & Africa Selective Cox-2 Inhibitors Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 56. Turkey Selective Cox-2 Inhibitors Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 57. Saudi Arabia Selective Cox-2 Inhibitors Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 58. U.A.E Selective Cox-2 Inhibitors Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 59. Boehringer-Ingelheim Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 60. TerSera Therapeutics Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 61. Iroko Pharmaceuticals Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 62. Apotex Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 63. Yung Shin Pharmaceutical Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 64. Breckenridge Pharmaceutical Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 65. Meda Pharmaceuticals Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 66. Cipla Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 67. Glenmark Pharmaceuticals Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 68. Teva Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 69. PuraCap Pharmaceutical Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 70. Almirall Limited Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 71. Lupin Pharmaceuticals Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 72. Aurobindo Pharma Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 73. Pfizer Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 74. Mylan Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 75. Takeda Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 76. Bayer Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 77. Novacap Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 78. Abbott Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 79. Geri-Care Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 80. Perrigo Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 81. Kopran Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 82. Merck Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 83. Hengrui pharmaceutical Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 84. Kelun Group Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 85. Qilu Pharmaceutical Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 86. Taro Pharmaceuticals  Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 87. Bottom-up and Top-down Approaches for This Report
    Figure 88. Data Triangulation
    Figure 89. Key Executives Interviewed